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Up-regulation of CRKL by microRNA-335 
methylation is associated with poor prognosis 
in gastric cancer
Jia‑kui Zhang†, Yong‑shuang Li†, Chun‑dong Zhang and Dong‑qiu Dai*
Abstract 
Background: MicroRNAs have been suggested to play a vital role in regulating carcinogenesis, tumor progression 
and invasion. MiR‑335 is involved in suppressing metastasis and invasion in various human cancers. However, the 
mechanisms responsible for the aberrant expression of miR‑335 in gastric cancer (GC) remain unknown.
Methods: Expression of miR‑335 in four GC cell lines and 231 GC tissues was determined by real‑time quantitative 
reverse transcriptase‑polymerase chain reaction (qRT‑PCR). DNA methylation status in the CpG islands upstream of 
miR‑335 in GC cell lines and tissues was determined by methylation‑specific PCR and bisulfite sequence‑PCR. The 
effects of the demethylating agent 5‑aza‑2′‑deoxycytidine on cell proliferation, apoptosis, cell cycle, migration, and 
invasion were investigated in GC cell lines.
Results: Cancer‑specific methylation was detected in the upstream CpG‑rich regions of miR‑335, which dramatically 
silenced its transcriptional activity in GC cell lines and tissues. Low levels of miR‑335 expression and high levels of 
miR‑335 methylation in GC tissues were associated with poor clinical features and prognosis. Restoration of miR‑
335 expression in GC cells promoted cell apoptosis, inhibited tumor cell migration, invasion, and proliferation, and 
arrested the cell cycle at G0/G1 phase. Overexpression of miR‑335 significantly reduced the activity of a luciferase 
reporter containing the 3′ untranslated region of V‑crk avian sarcoma virus CT10 oncogene homolog‑like (CRKL).
Conclusions: MiR‑335 functions as a tumor suppressor and may be silenced by promoter hypermethylation. It plays 
a role in inhibiting tumor cell migration, invasion, and proliferation, arresting the cell cycle at G0/G1 phase, and pro‑
moting apoptosis in GC cells through targeting CRKL.
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Background
Gastric cancer (GC) is a common cancer and the sec-
ond leading cause of cancer-related deaths worldwide 
[1, 2]. Despite considerable improvements in surgical 
techniques, innovations in clinical diagnostics, and the 
development of new chemotherapy regimens, the clini-
cal outcome for patients with advanced GC remains poor 
[3]. A better understanding of the molecular mechanisms 
underlying GC will therefore improve the prevention, 
diagnosis, and therapy of this disease.
MicroRNAs (miRNAs) are a class of endogenous small 
non-coding RNAs of 21–25 nucleotides that regulate the 
expression of target genes in a post-transcriptional man-
ner, leading to mRNA degradation or inhibition of transla-
tion through imperfect hybridization to the 3′ untranslated 
region (3′UTR) of the target mRNAs [4]. miRNAs are 
promising biomarkers and are involved in regulating 
diverse biologic processes. They can function as tumor 
suppressors or oncogenes, depending on the target gene.
MiR-335 expression was recently shown to be dereg-
ulated in several human cancers, and to act as a tumor 
suppressor in various tumor types [5–7]. Dysregulation 
Open Access
Cancer Cell International
*Correspondence:  daidq1963@sina.com 
†Jia‑kui Zhang and Yong‑shuang Li contributed equally to the writing of 
this article 
Department of Gastroenterological Surgery, The Fourth Affiliated Hospital 
of China Medical University, 4 Chongshan Road, Shenyang 110032, 
People’s Republic of China
Page 2 of 14Zhang et al. Cancer Cell Int  (2017) 17:28 
of miRNAs can be caused by epigenetic modifications, 
including DNA methylation and the covalent modifi-
cation of histone protein, which do not directly change 
the DNA sequence. DNA methylation is a heritable and 
enzyme-induced modification in humans. A high fre-
quency of CpG dinucleotides is often found in the 5′UTR 
and first exon of most genes, and these dinucleotides 
control the expression of these genes by modulating their 
methylation status [8]. Methylation of CpG islands in the 
gene promoter has been strongly linked to the silencing 
of tumor-suppressor gene expression in cancer [9–14]. 
Several tumor-associated miRNAs have been reported 
to be silenced by aberrant hypermethylation of their pro-
moter regions in various cancers, including miR-9, miR-
137, miR-34b, miR-124a, miR-342, and miR-127 [10, 11, 
15, 16]. However, the mechanisms responsible for the 
downregulation of miR-335 are unclear, and may involve 
various factors, including genetic and epigenetic modifi-
cations. Hypermethylation of the promoter region may 
also play an important role in silencing miR-335 in GC.
In the present study, we investigated the role of miR-335 
methylation and expression in GC cell lines and tumor tis-
sues, the clinicopathological and prognostic values of miR-
335 methylation and expression in patients with GC, and 
the functional impact of ectopic miR-335 expression on 
GC cell invasion, cell cycle, apoptosis, and proliferation.
Methods
Clinical tissue samples and cell lines
A total of 231 pairs of fresh GC and adjacent non-tumor 
gastric tissues were obtained from patients with a diagno-
sis of primary GC who underwent elective surgery at The 
Cancer Institute of China Medical University (Shenyang, 
China) between June 2009 and June 2011, after obtain-
ing written informed consent. None of the patients had 
received chemotherapy or radiotherapy before surgery. 
The use of tissues for this study was approved by the eth-
ics committee of The Fourth Affiliated Hospital of China 
Medical University. The median age of the patients (123 
men and 108 women) was 61 years (range 26–85 years). 
Survivors were followed up by phone or mail for a 
median period of 31  months (range 3–60  months). The 
study parameters included age, sex, stage, histological 
grade, macroscopic type, Lauren’s grade, venous invasion, 
peritoneal dissemination, tumor size, depth of invasion, 
lymph node metastasis, invasion into lymphatic vessels, 
and distant metastasis. TNM classification definitions 
were made according to the American Joint Committee 
on Cancer TNM staging system (7th edition). Cancer his-
tological grade was assessed according to the criteria set 
by the World Health Organization. Fresh samples were 
snap frozen in liquid nitrogen immediately after resec-
tion and stored at −80 °C.
The immortalized normal gastric mucosal epithe-
lium cell line (GES-1) and four GC cell lines (SGC-7901, 
MKN-45, BGC-823, and AGS) were purchased from 
Shanghai Institutes for Biological Sciences, Chinese 
Academy of Science (Shanghai, China) in July 2014. All of 
the cell lines have been tested and authenticated by STR 
profiling (ATCC) in July 2014. All cells were cultured in 
RPMI 1640 supplemented with 10% heat-inactivated fetal 
bovine serum, 100  µg/mL streptomycin, and 100  U/mL 
penicillin in a humidified cell incubator at 37 °C with an 
atmosphere of 5% CO2. Cells were treated with 3 µmol/L 
5-aza-2′-deoxycytidine (5-aza; Sigma–Aldrich, St Louis, 
MO, USA) for 72  h to inhibit DNA methyltransferase 
(DNMT) activity. Cells treated with dimethyl sulfoxide 
served as a control. An initial report indicated that these 
conditions could achieve maximal demethylation with 
minimal toxic effects [17]. SGC-7901 cells were plated 
1 day before transfection using Lipofectamine 2000 rea-
gent (Invitrogen, USA) in Opti-MEM (Gibco, USA). A 
final concentration of 50 nM of RNA mimic or 200 nM 
of inhibitor and their respective negative control (NCs) 
were transfected using Lipofectamine 2000 (Invitrogen, 
USA) according to the manufacturer’s instructions. Cells 
were harvested for further experiments after 24 or 48 h.
Extraction of total RNA and real‑time polymerase chain 
reaction
Total RNA was extracted from cell lines using RNAiso 
Plus (Takara Bio Inc., Shiga, Japan), according to the 
manufacturer’s protocol. The concentration was deter-
mined by ultraviolet–visible spectrophotometry (A260/
A280  >  1.9). Quantitative polymerase chain reaction 
(PCR) was performed using an All-in-One miRNA quan-
titative RT-PCR Detection Kit (GeneCopoeia, Rockville, 
MD) according to the manufacturer’s instructions. The 
primer sequences were as follows: (forward) 5′-TCAAG 
AGCAATAACGAAAAATGT-3′ (reverse) 5′-GCTGTC 
AACGATACGCTACGT-3′ (miR-335) and (forward) 
5′-CGCTTCGGCAGCACATATAC-3′, 5′-TTCACGAAT 
TTGCGTGTCAT-3′ (U6). U6 mRNA levels were used as 
an endogenous reference for normalization. Results were 
normalized to the concentration of U6 RNA and calcu-
lated using the 2−CT method, where ∆CT was the dif-
ference in threshold cycle (CT) values.
For detection of V-crk avian sarcoma virus CT10 
oncogene homolog-like (CRKL) mRNA, first-strand 
cDNA was synthesized using a High-Capacity cDNA 
Reverse Transcription Kit (ABI, USA). RT-primers for 
CRKL mRNA were synthesized as follows: 5′-CATTCC 
CGGGCGGCTCTCTC-3′ (forward) and 5′-CACGCCT 
TAGCCCGGCAGAC-3′ (reverse) by Sangon Biotech 
Company (Shanghai, China). Real-time quantitative PCR 
(qRT-PCR) was performed according to the TaqMan 
Page 3 of 14Zhang et al. Cancer Cell Int  (2017) 17:28 
Gene Expression Assays protocol (ABI, USA). The relative 
quantification of CRKL mRNA in cell lines was normal-
ized using glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) by the 2−CT method. The PCR program 
was designed as follows: 95 °C for 10 min, followed by 35 
cycles of 95 °C for 15 s, 60 °C for 30 s, and 72 °C for 45 s. 
All qRT-PCRs were performed in triplicate.
Luciferase assay
CRKL was predicted as a potential target of miR-335 by 
bioinformatics analysis (TargetScan, http://www.targets-
can.org/). Plasmids containing wild-type and mutant 
Luc-CRKL 3′UTR were synthesized (GeneCopoeia) and 
used in luciferase reporter assays. These plasmids con-
tained firefly luciferase and Renilla luciferase as tracking 
genes. Luciferase activity assays were performed follow-
ing the manufacturer’s protocols. Briefly, SGC-7901 cells 
were seeded in six-well plates, cotransfected with miR-
335 mimic or NC and lentiviral constructs containing 
the target gene with wild-type or mutated 3′UTR, using 
Lipofectamine 2000. Firefly and Renilla luciferase activi-
ties were measured 48  h after transfection using a Luc-
Pair miR Luciferase Assay Kit (GeneCopoeia) according 
to the manufacturer’s recommendations. Activities were 
normalized to Renilla luciferase. Results represent three 
independent experiments, each performed in triplicate.
Extraction of genomic DNA and bisulfite modification
Genomic DNA was isolated from the cultured cells and 
specimens using a Universal Genomic DNA Extraction 
Kit Ver3.0 (Takara Bio Inc.). DNA concentration and 
purity were controlled by ultraviolet–visible spectropho-
tometry (1.8 < A260/A280 < 2.0). Genomic DNA (2 µg) 
was then subjected to bisulfite conversion using an EZ 
DNA Methylation-Gold Kit (Zymo Research Corpora-
tion, Orange, CA, USA). The bisulfite conversion reac-
tion was incubated in a PCR thermocycler at 98  °C for 
10 min, followed by 64 °C for 2.5 h, with a final incuba-
tion at 4  °C for up to 20 h. The modified DNA samples 
were dissolved in ddH2O and stored at −80 °C.
DNA methylation bisulfite‑modified sequencing
The sequence of miR-335 was searched using the University 
of California Santa Cruz’s Genome Bioinformatics resource 
[18]. Scanning for CpG islands in the submitted sequence 
identified four CpG islands in Methprimer (http://www.
urogene.org/index.html). The Berkeley Drosophila 
Genome Project (BDGP) (http://fruitfy.org:9005/seq_tools/
promoter.html) submitted three promoter regions with 
scores  >  0.90: 128–178 base pairs (bp), 935–985  bp, and 
1740–1790  bp. We confirmed that the promoter of miR-
335 lay within the range of the CpG islands.
Bisulfite-modified sequencing (BSP) primers were 
designed using Methyl Primer Express® software (v 1.0; 
Thermo Fisher Scientific. USA): forward 5′-TAAAGGGG 
GTTTTGTTTTTTTAATT-3′ and reverse 5′-CCCACA 
AACTACCCACAAAC-3′. The whole process was as 
follows: DNA methylation bisulfite modification; PCR 
amplification, electrophoresis, and retrieval; PCR prod-
ucts connected to the pUC18-T vector and transforma-
tion; blue/white plaque selection; extraction of plasmids; 
and finally sequencing of the DNA. The sequencing 
process was performed by Sangon Biotech (Shanghai, 
PR China) with genomic DNA from the cell lines and 
sequencing primers provided by our group.
Methylation‑specific PCR
We designed primers for methylation-specific PCR 
(MSP) using Methyl Primer Express software: methylated 
forward 5′-GGTTTTAAAAGTCGGTGTTTATTC-3′, 
reverse 5′-AACTACAACCACTCCGACGTA-3′; and 
unmethylated forward 5′-GGGTTTTAAAAGTTGGTG 
TTTATTT-3′, reverse 5′-AACAACTACAACCACTCCA 
ACATA-3′. The amplicon sizes were 125 and 127 bp for 
methylated and unmethylated products, respectively. We 
used treated DNA in PCR amplification with TaKaRa 
Taq Hot Start Version (code number DR007A; Takara 
Bio Inc.). The PCRs were conducted under the follow-
ing thermocycling conditions: 5 min at 94 °C, 40 cycles of 
30 s at 94 °C, 30 s at 58 °C, 30 s at 72 °C, and a final incu-
bation at 72 °C for 10 min. All PCRs were performed with 
negative and positive controls using completely methyl-
ated and unmethylated human control DNA, respec-
tively, and water. Aliquots of 5 µL of the total 20 µL of the 
PCR mixture were loaded onto 3% agarose gels, stained 
with ethidium bromide, and visualized directly under 
ultraviolet illumination. MSP assays were repeated at 
least three times for each sample to determine the repro-
ducibility of the results.
Western blot
Cells were lysed using RIPA lysis buffer containing Pro-
tease Inhibitor Cocktail (Pierce, USA), and the protein 
concentration was measured by BCA Protein Assay Kit 
(Pierce). Proteins were electrophoresed and electrotrans-
ferred. The membranes were probed using antibodies 
against CRKL (1:1000) and GAPDH (1:5000), with horse-
radish peroxidase-conjugated secondary antibodies. Pro-
tein quantities were detected using GAPDH as a loading 
control.
Transwell cell migration and Matrigel invasion assays
We determined the invasion ability of 5-aza-treated 
SGC-7901 and NC cells in  vitro by Transwell cell 
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migration and Matrigel invasion assays. Cells were plated 
in 24-well Transwell plates (8  mm pore size; Corning, 
NY, USA) to measure their migratory and invasive abili-
ties. For Transwell migration assays, 2.5 × 104 cells were 
added to the top chamber lined with a non-coated mem-
brane. For invasion assays, chamber inserts were coated 
with 200  mg/mL Matrigel (BD Biosciences, San Jose, 
CA, USA), dried overnight under sterile conditions, 
and 5 ×  104  cells were then placed in the top chamber. 
In both assays, cells were suspended in medium without 
serum or growth factors, and medium supplemented 
with serum was used as a chemoattractant in the lower 
chamber. After 24  h incubation at 37  °C with 5% CO2, 
the number of cells that had migrated to the basal side of 
the membrane was quantified by counting 16 independ-
ent symmetrical visual fields under a microscope. Cell 
morphology was observed by staining with hematoxy-
lin–eosin. Assays were conducted in five independent 
experiments.
Cell proliferation assay and cell cycle analysis
The proliferation abilities of 5-aza-treated SGC-7901, 
MKN-45 and their NC cells were determined by MTT 
(3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenylte-trazolium 
bromide) assay using a Cell Proliferation Kit 1 (Roche 
Applied Science), according to the manufacturer’s 
instructions. For cell cycle analysis, cells were treated 
by ethanol fixation, RNase A, and propidium iodide (PI) 
staining, and then detected by flow cytometry using a 
FACSCalibur (Becton–Dickinson, USA). Cell popula-
tions in the G0/G1, S, and G2/M phases were quantified 
by Modfit software (Becton–Dickinson), allowing for cell 
debris and fixation artifacts.
Cell apoptosis analysis
Cell apoptosis rate was calculated using an Annexin 
V-FITC Apoptosis Detection Kit I (BD Pharmingen, 
USA) according to the product instructions. Briefly, 
cells were washed with phosphate-buffered saline and 
resuspended in 1× Binding Buffer at a concentration of 
1 × 106 cells/mL, followed by the addition of 5 µL fluo-
rescein isothiocyanate (FITC)–Annexin V and 5 µL PI to 
100  µL of the cell suspension, incubation for 15  min in 
the dark, and the addition of 400 µL 1× Binding Buffer. 
Apoptosis was analyzed by flow cytometry (FACSCali-
bur, Becton–Dickinson) using CellQuest software (Bec-
ton–Dickinson). Apoptotic cells were defined as Annexin 
V-FITC-positive, PI-negative cells.
Wound‑healing assay
5-Aza-treated SGC-7901 and NC cells were grown to 
confluence. A wound was made through the monolayer 
using a p20 pipette tip, and the migration rate was 
calculated according to the equation: percentage wound 
healing = [(wound length at 0 h) − (wound length at 4, 6, 
20, or 27 h)]/(wound length at 0 h) × 100. Two independ-
ent experiments were performed.
Statistical analysis
Statistical analyses were performed using SPSS for Win-
dows statistical software, version 19.0 (SPSS, Chicago, 
IL, USA). Data are presented as the mean  ±  standard 
deviation (SD) from at least three independent experi-
ments. Differences between groups were analyzed using 
Student’s t tests and nonparametric Mann–Whitney U 
tests. The relationship between miR-335 expression levels 
and methylation status in gastric tissues was calculated 
using χ2 tests (2 ×  2 table, Pearson’s analysis). Correla-
tions between methylation status, miR-335 expression 
levels, and clinicopathologic parameters were analyzed 
by χ2 with Mann–Whitney U tests for two groups and 
Kruskal–Wallis tests for three or more groups. Survival 
curves were plotted using the Kaplan–Meier method and 
survival differences were assessed using the log-rank test. 
Univariate and multivariate Cox proportional hazards 
models were used to assess survival results. Disease-free 
survival (DFS) was measured from the date of surgery to 
the time of recurrence, death, or censoring. All P values 
were two-sided, and differences were considered to be 
statistically significant when P < 0.05.
Results
Downregulation of miR‑335 in human GC cell lines
We examined the expression levels of miR-335 in five 
human gastric cell lines (SGC-7901, MKN-45, BGC-823, 
AGS, and GES-1) by qRT-PCR. MiR-335 was down-
regulated in GC cell lines (SGC-7901, MKN-45, BGC-
823, and AGS) compared with normal gastric epithelial 
cells (GES-1) (MKN-45, 0.154  ±  0.016-fold, P  <  0.01; 
SGC-7901, 0.138  ±  0.013-fold, P  <  0.01; BGC-823, 
0.432  ±  0.076-fold, P  <  0.01; AGS, 0.749  ±  0.072-fold, 
P = 0.01) (Fig. 1a).
Relative expression levels of miR‑335 in human GC tissues 
and correlation with clinicopathological characteristics
To determine if miR-335 expression was associated with 
GC, we compared miR-335 expression levels in a large 
cohort of 231 primary GC tissues with levels in pair-
matched adjacent non-tumor tissues, using qRT-PCR. 
MiR-335 levels were significantly downregulated in GC 
tissues compared with paired adjacent non-tumor tis-
sues (P < 0.001; Fig. 1b). We divided the 231 patients with 
GC into high-miR-335-expression (n  =  116) and low-
miR-335-expression groups (n = 115), according to miR-
335 expression levels above or below the median value, 
respectively. Low miR-335 expression was significantly 
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associated with tumor size (P = 0.030), venous invasion 
(P = 0.027), peritoneal dissemination (P = 0.027), lymph 
node metastasis (P = 0.033), poor pT stage (P = 0.040), 
poor pN stage (P = 0.038), poor TNM stage (P = 0.005), 
and invasion into lymphatic vessels (P = 0.041) (Table 1).
We also analyzed the association between miR-335 
expression and survival duration using Kaplan–Meier 
analysis with the log-rank test. High miR-335 expression 
was significantly associated with better DFS (P = 0.013) 
(Fig. 2a). 
CRKL levels in GC cells and role as target of miR‑335
To identify the potential target genes of miR-335, we 
integrated bioinformatic algorithms using the publicly 
available database TargetScan (http://www.targetscan.
org). Among a total of 255 genes that were potentially 
targeted by miR-335 (Fig.  3a), CRKL may contribute to 
the metastasis, invasion, and proliferation of GC.
We detected CRKL expression in four GC cell 
lines (SGC-7901, MKN-45, BGC-823, AGS) and one 
immortalized gastric epithelial cell line (GES-1) by qRT-
PCR and western blotting. CRKL mRNA levels were 
similar in all four GC cell lines and GES-1 cells (P > 0.05) 
(Fig.  1c). However, western blot analysis indicated that 
CRKL protein expression levels were increased in GC 
cell lines compared with GES-1 cells (Fig.  1d), suggest-
ing post-transcriptional regulation of CRKL expression 
in GC cells.
To validate the miRNA–target interactions, we evalu-
ated CRKL expression in SGC-7901 cells transfected with 
either miR-335 mimic or NC. Overexpression of miR-335 
dramatically suppressed endogenous CRKL at the pro-
tein level compared with NC, as demonstrated by west-
ern blot and qRT-PCR (Fig.  3c–f). To confirm if CRKL 
was regulated by miR-335 through direct binding to its 
3′UTR, wild-type and mutant CRKL 3′UTRs were con-
structed and cloned downstream of the luciferase gene 
in a pGL3-control vector, followed by luciferase assay 
in SGC-7901 cells. The wild-type 3′UTR reporter con-
struct was associated with significantly lower luciferase 
Fig. 1 Expression of miR‑335 and CRKL in GC cell lines and tissues. a Analysis of miR‑335 expression levels in cell lines by qRT‑PCR. MiR‑335 expres‑
sion levels in four GC cell lines were significantly down‑regulated compared with levels in normal gastric mucosal epithelial cells (GES‑1) (P < 0.01). 
Each bar represents fold change relative to GES‑1 cells calculated by 2−CT. **P < 0.01 between groups. b Expression levels of MiR‑335 in paired 
GC and adjacent normal tissues. Quantification of miR‑335 by qRT‑PCR. c Analysis of transcription levels of CRKL in cell lines by qRT‑PCR. There was 
no significant difference in CRKL mRNA levels between the four GC cell lines (SGC‑7901, MKN‑45, BGC‑823, and AGS) and GES‑1 cells (P > 0.05). d 
CRKL protein expression levels in GC cell lines (SGC‑7901, MKN‑45, BGC‑823, and AGS) was significantly up‑regulated compared with GES‑1 cells, 
determined by western blot. Numbers above the blot indicate normalized protein amounts relative to the negative control, as determined by 
densitometry
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activity in cells expressing miR-335 compared with those 
expressing NC miRNA. In contrast, there was no signifi-
cant difference in relative luciferase activities of pGL3-
CRKL-MUT reporters in SGC-7901 cells transfected 
Fig. 2 Kaplan–Meier plots of disease‑free survival in relation to miR‑
335 expression and methylation levels. a Kaplan–Meier disease‑free 
survival curves in relation to miR‑335 expression levels. Disease‑free 
survival of patients with low miR‑335 expression (n = 115) was 
significantly lower than that of patients with high miR‑335 expres‑
sion (n = 116; log‑rank test; P = 0.013). b Kaplan–Meier disease‑free 
survival curves in relation to miR‑335 methylation levels. Disease‑free 
survival of patients with hypermethylation of miR‑335 (n = 127) was 
significantly lower than that of patients with hypomethylation of miR‑
335 (n = 104; log‑rank test; P = 0.035)
Table 1 The correlation between expression levels of miR-
335 in GC specimens and GC clinicopathologic features
Based on Pearson χ2 test and Fisher exact test







n % n %
Age 0.728
 >55 87 76 90 78
 ≤55 28 24 26 22
Sex 0.641
 Male 63 55 60 52
 Female 52 45 56 48
Histological grade 0.616
 Well 39 34 43 37
 Poor 76 66 73 63
Tumor size (cm) 0.030*
 ≤3.5 24 21 39 34
 >3.5 91 79 77 66
Macroscopic type 0.702
 Early stage 3 3 3 3
 Borrmann I + II 10 9 14 12
 Borrmann III + IV 102 88 99 85
Lauren’s grade 0.813
 Intestinal 36 31 38 33
 Diffuse 79 69 78 67
Venous invasion 0.027*
 Absent 81 70 96 83
 Present 34 30 20 17
Liver metastasis 0.669
 Absent 105 91 104 90
 Present 10 9 12 10
Peritoneal dissemination 0.027*
 Absent 95 83 107 92
 Present 20 17 9 8
pT stage 0.040*
 T1 1 1 5 4
 T2 20 17 24 21
 T3 30 26 42 36
 T4 64 56 45 39
pN stage 0.038*
 N0 + N1 29 25 44 38
 N2 + N3 86 75 72 62
Metastasis lymph node 0.033*
 Negative 26 23 41 35
 Positive 89 77 75 65
Invasion into lymphatic vessels 0.041*
 Negative 87 76 100 86
 Positive 28 24 16 14
AJCC stage 0.005*
 I + II 48 42 70 60
 III + IV 67 58 46 40
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with miR-335 or NC miRNA (Fig.  3b). Overall, these 
results indicated that CRKL was directly targeted by 
miR-335, and that CRKL expression in GC was negatively 
regulated by miR-335.
Downregulation of miR‑335 by DNA methylation in GC cell 
lines and tissues
Tumor suppressor miRNAs, including miR-335, 
have been reported to be silenced by aberrant DNA 
Fig. 3 CRKL is a target of miR‑335. a MiR‑335 target‑site residues in the CRKL 3′UTR are highly conserved among different species. b Direct interac‑
tion between miR‑335 and CRKL was detected by dual‑luciferase reporter assay. Over‑expression of miR‑335 in SGC‑7901 cells (SGC‑7901/miR‑335) 
significantly decreased the luciferase signal of CRKL/pMIR/WT compared with the negative control (NigmiR), while mutation of the putative miR‑
335‑binding site abolished this suppressive effect. **P < 0.01). c qRT‑PCR analysis of miR‑335 in SGC‑7901 cells transfected with miR‑335‑mimic or 
NC miRNA. Relative expression of miR‑335 in SGC‑7901 cells transfected with miR‑335 mimic was significantly higher than in NC cells. ***P < 0.001 
between groups. d qRT‑PCR analysis of miR‑335 in SGC‑7901 cells transfected with miR‑335 inhibitor or NC. Relative expression of miR‑335 in SGC‑
7901 cells transfected with miR‑335 inhibitor was significantly lower than in NC cells. ***P < 0.001 between groups. e Effect of miR‑335 on CRKL 
mRNA levels in SGC‑7901 cells detected by qRT‑PCR. Over‑expressing miR‑335 had no significant effect on CRKL mRNA levels in SGC‑7901 cells.  
f Effect of miR‑335 on CRKL protein expression in SGC‑7901 cells detected by western blot analysis. CRKL protein expression was significantly sup‑
pressed by over‑expressing miR‑335 in SGC‑7901 cells
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hypermethylation. We therefore investigated the mecha-
nisms whereby miR-335 functions in GC cells, with an 
emphasis on epigenetics. We determined if miR-335 
expression was silenced by DNA methylation by examin-
ing the reactivation of miR-335 expression in GC and NC 
cells following treatment with the demethylating agent 
5-aza. MiR-335 expression levels recovered by 2–3-fold 
after 5-aza treatment (Fig.  4a). We also detected CRKL 
expression levels in 5-aza-treated GC and NC cells by 
qRT-PCR and western blot. CRKL mRNA levels were 
similar in 5-aza-treated and NC cells (P > 0.05) (Fig. 4b), 
but CRKL protein levels were significantly reduced 
after 5-aza treatment, as indicated by western blotting 
(Fig. 4c). Furthermore, we detected CpG island methyla-
tion of miR-335 in GC cell lines by BSP analysis of multi-
ple clones in the cell lines. Bisulfite sequencing in all four 
GC cell lines confirmed marked methylation of the pro-
moter region of miR-335 (Fig. 4d).
DNA methylation levels in GC cell lines and tissues 
were analyzed by MSP. Hypermethylation and hypo-
methylation of PCR products were detected by electro-
phoresis. All four GC cell lines showed hypermethylation 
(Fig. 5a). Among the 231 GC tissue samples, 127 samples 
showed hypermethylation (55%) and 104 samples showed 
hypomethylation (45%) (Fig.  5b). The MSP results were 
used to analyze correlations between miR-335 expression 
and clinicopathologic features in patients with GC.
We also analyzed the correlations between miR-335 
methylation status and clinicopathologic characteristics. 
Hypermethylation of the miR-335 gene promoter region 
was associated with tumor size (P  =  0.004), miR-335 
expression level (P < 0.001), and invasion into lymphatic 
Fig. 4 MiR‑335 was down‑regulated by DNA methylation in GC cell lines and tissues. a SGC‑7901 and MKN‑45 cells were cultured in the absence 
or presence of the demethylating agent 5‑aza for 72 h. MiR‑335 levels in treated cells were significantly higher than those in control cells. Error bars 
represent the SD from five replicates. **P < 0.01 between groups. b SGC‑7901 and MKN‑45 cells were cultured in the absence or presence of 5‑aza 
for 72 h. CRKL mRNA levels were similar in treated and negative control cells (P > 0.05). Error bars represent the SD from five replicates.  
c CRKL expression levels were significantly reduced after 5‑aza treatment, indicated by western blot analysis. d DNA methylation BSP in GC cell lines. 
Five single clones are represented for each sample. CpG islands are depicted and each CpG site is indicated by a vertical bar. Black and white circles 
represent hypermethylation and hypomethylation, respectively
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vessels (P = 0.001) (Table 2). These results indicated that 
patients with GC with low miR-335 expression, meta-
static lymph nodes, invasion into lymphatic vessels, and 
large tumor size may have hypermethylation in the miR-
335 gene promoter region.
We also analyzed the association between miR-335 
methylation status and survival duration using Kaplan–
Meier analysis with the log-rank test. Patients were 
divided into hypermethylation (n = 127) and hypometh-
ylation (n = 104) groups. Kaplan–Meier estimation indi-
cated that hypomethylation of miR-335 was significantly 
associated with better DFS (P = 0.035) (Fig. 2b).
Effects of ectopic miR‑335 expression on cell apoptosis, 
proliferation, migration, and invasion, and cell cycle 
in SGC‑7901 cells
We investigated the contribution of DNA methylation 
of miR-335 to gastric carcinogenesis by determining the 
effect of DNA methylation of miR-335 on the phenotype 
of GC cells. SGC-7901 and MKN-45 cells were treated 
with 5-aza at a final concentration of 3 µmol/L, and miR-
335 expression was analyzed after 72 h. 5-Aza treatment 
increased miR-335 expression in SGC-7901 and MKN-45 
cells, as confirmed by qRT-PCR (Fig.  4a). The effect on 
CRKL expression was validated by western-blot analysis 
(Fig. 4c). The migration and invasive capacities of SGC-
7901 cells, assessed by Transwell and wound-healing 
assays, respectively, were significantly reduced following 
restoration of miR-335 expression (Figs. 6a, b, 7a, b). The 
proliferation abilities of 5-aza-treated, NC-treated, and 
parental gastric cancer cells were assessed by MTT assay. 
Cell proliferation of SGC-7901 and MKN-45 cells was 
significantly reduced by 5-aza compared with NC and 
parental cells (Fig. 7c). We also investigated the effect of 
restoration of miR-335 expression on GC cell cycle. The 
cell cycle in SGC-7901 cells was significantly arrested at 
G0/G1 phase when miR-335 expression was restored, as 
shown by flow cytometry (Fig. 8a, b). The percentage of 
SGC-7901 cells in G0/G1 phase increased from 62.43 to 
81.69% (P < 0.05), S phase cells decreased from 28.83 to 
10.62% (P < 0.05), and G2/M phase cells decreased from 
8.74 to 7.41% (P < 0.05).
To clarify the biological functions of miR-335 in GC, 
we investigated its effect on GC cell apoptosis. The apop-
tosis rates of NC and 5-aza-treated cells were 9.61 and 
16.11%, indicating that restoration of miR-335 expression 
significantly increased apoptosis of GC cells (P < 0.01).
Discussion
Epigenetic mechanisms are important for regulating cell 
growth and development in mammals. miRNAs repre-
sent a class of small non-coding RNAs that regulate gene 
expression at the post-transcriptional level, and subse-
quently control crucial physiological processes. Aber-
rant expression of miRNAs has recently been reported to 
have an impact on human carcinogenesis. Expression of 
miRNAs may be regulated by various processes, includ-
ing DNA methylation and histone modification, [17, 19, 
20] DNA copy abnormalities [21], mutation [22], fail-
ure of post-transcriptional regulation [23], regulation by 
transcription factors [24], and defective miRNA biogen-
esis pathways [25]. DNA methylation is one of the most 
important types of epigenetic modifications, and has 
frequently been reported to regulate gene transcription 
Fig. 5 MSP in GC cell lines and tissues. Presence of a line under the M or U lanes indicates hypermethylation and hypomethylation sequences, 
respectively. Normal blood (NB) and in vitro methylated DNA (IVD) were used as positive controls for hypomethylation and hypermethylation, 
respectively. Abbreviations: M hypermethylation, U hypomethylation, G gastric cancer tissue
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during tumorigenesis [26]. Promoter hypermethylation is 
associated with inhibition of gene transcription and func-
tion of tumor suppressor genes. Several tumor-suppres-
sive miRNAs are known to be silenced by aberrant DNA 
methylation of their promoter regions in human cancers, 
including miR-34, miR-129, miR-137, miR-193a, miR-
203, and miR-148a [27–30]. In this study, we focused on 
miR-335 silencing by methylation in GC cells.
MiR-335 is transcribed from the genomic region of 
chromosome 7q32.2 and has been shown to be aber-
rantly expressed in malignant tumors, and to play cru-
cial roles in tumor initiation and progression [31]. Cao 
et al. [5] observed that miR-335 expression was reduced 
in epithelial ovarian cancer tissue samples, especially in 
omental metastases, and low miR-335 levels emerged as 
an independent prognostic factor for poor overall and 
relapse-free survival; Wang et al. [32] also identified miR-
335 as a tumor suppressor by targeting the ROCK1 gene 
and inhibiting osteosarcoma cell migration and invasion. 
However, the detailed expression pattern and potential 
role of miR-335 in GC remains unclear. Yan et  al. [33] 
reported that GC patients with high levels of miR-335 
had a high frequency of recurrence. In contrast, Xu et al. 
[34] reported that miR-335 was dramatically downregu-
lated in GC cell lines, and low expression of miR-335 was 
associated with poor pT stage, poor pN stage, and inva-
sion into lymphatic vessels. Further studies are therefore 
needed to clarify the biological functions and mecha-
nisms of miR-335 in GC. The current study provides the 
first investigation focusing on epigenetic modifications of 
miR-335 in GC.
The results of the current study showed that miR-
335 was dramatically downregulated in GC cell lines 
and tissue specimens, suggesting that low expres-
sion of miR-335 was significantly associated with GC. 
Clinicopathological analysis also found that miR-335 
expression was negatively correlated with tumor size, 
venous invasion, peritoneal dissemination, lymph node 
metastasis, poor pT stage, poor pN stage, poor TNM 
stage, and invasion into lymphatic vessels, while low 
Table 2 Association between  the promoter region meth-









n % n %
Age 0.830
 >55 98 77 79 76
 ≤55 29 23 25 24
Sex 0.371
 Male 71 56 52 50
 Female 56 44 52 50
Histological grade 0.765
 Well 44 35 38 37
 Poor 83 65 66 63
Tumor size (cm) 0.004*
 ≤3.5 25 20 38 37
 >3.5 102 80 66 63
Macroscopic type 0.843
 Early stage 4 3 2 2
 Borrmann I + II 13 10 11 11
 Borrmann III + IV 110 87 91 87
Lauren’s grade 0.347
 Intestinal 44 35 30 29
 Diffuse 83 65 74 71
Venous invasion 0.922
 Absent 97 76 80 77
 Present 30 24 24 23
Liver metastasis 0.622
 Absent 116 91 93 89
 Present 11 9 11 11
Peritoneal dissemination 0.223
 Absent 108 85 94 90
 Present 19 15 10 10
pT stage 0.434
 T1 3 2 3 3
 T2 23 18 21 20
 T3 35 28 37 36
 T4 66 52 43 41
pN stage 0.240
 N0 + N1 36 28 37 36
 N2 + N3 91 72 67 64
Metastasis lymph node 0.058
 Negative 30 24 37 35
 Positive 97 76 67 65
Invasion into lymphatic vessels 0.001*
 Negative 93 73 94 90
 Positive 34 27 10 10
AJCC stage 0.197
 I + II 60 47 58 56
 III + IV 67 53 46 44
Based on Pearson χ2 test and Fisher exact test










n % n %
MiR‑335 level <0.001*
 Low expression 78 61 37 36
 High expression 49 39 67 64
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expression of miR-335 was associated with shorter DFS 
in GC patients.
In the present study, we analyzed the methylation 
status of miR-335 in GC cell lines using BSP and MSP. 
Hypermethylation of the promoter region of miR-335 
was relatively common in GC cell lines, and was also 
detected in 55% of 231 GC tissue specimens by MSP. 
We analyzed the correlation between methylation status 
and miR-335 expression in GC tissues and showed that 
downregulated expression of miR-335 was significantly 
correlated with CpG island DNA hypermethylation in the 
promoter region. We also showed that miR-335 methyla-
tion status was associated with tumor size and invasion 
into lymphatic vessels in a large sample of patients with 
GC. These results suggest that promoter hypermeth-
ylation might repress miR-335 expression, and that low 
expression might in turn contribute to metastasis, prolif-
eration, and invasion in GC. Furthermore, we confirmed 
that miR-335 expression in GC cells was upregulated by 
the DNA methylation inhibitor 5-aza.
Functional studies demonstrated that restoration 
of miR-335 reduced cell proliferation, migration, and 
invasion, arrested the cell cycle, and increased GC cell 
apoptosis, indicating a potentially suppressive role for 
miR-335 in GC. We further explored the mechanisms 
whereby miR-335 regulates tumor invasion, metas-
tasis, proliferation, cell cycle, and apoptosis in GC by 
identifying miR-335 targets in GC carcinogenesis and 
progression. We searched for direct target genes by 
bioinformatics miRNA–mRNA 3′UTR matching, and 
found that CRKL included a putative miR-335-binding 
site within its 3′UTR. CRKL acts as a transcriptional 
activator in Bcr-Abl-expressing cells, and constitutes 
the major tyrosine phosphorylated protein in chronic 
myelogenous leukemia [35]. Protein-expression analy-
sis of activated phosphorylated CRKL in normal and 
Fig. 6 MiR‑335 inhibited GC cell invasion and metastasis in vitro. a Invasion and migration assays for SGC‑7901 cells treated with 5‑aza or NC. Rep‑
resentative fields of migrating (left) and invading (right) cells on membrane. b Migrating and invading SGC‑7901 cells were significantly reduced by 
5‑aza. Numbers of cells were counted in 16 independent symmetrical visual fields under a microscope (×400 original magnification) from five inde‑
pendent experiments. Results represent the means of the values from five independent experiments. Bars indicate SD. *P < 0.05 between groups
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malignant tissues indicated that CRKL was associated 
with malignant transformation, and was selectively 
up-regulated in numerous epithelial tumors, including 
gastric, prostate, ovary, and colon cancers [36]. Yeung 
et al. [37] found that CRKL was over-expressed in rhab-
domyosarcoma tissues and cell lines, and was involved 
in rhabdomyosarcoma tumor growth. Research on 
non-small cell lung cancer cell lines by Kim et  al. [38] 
showed that CRKL was amplified in diverse oncogenic 
lung cancer phenotypes, and RNA interference-medi-
ated knock-down of CRKL could significantly suppress 
the proliferation, survival, and migration of lung can-
cer cell lines. Natsume et al. [39] recently observed that 
CRKL protein was amplified in GC, and this report sug-
gests that CRKL may be a critical molecule and a pos-
sible therapeutic target involved in the initiation and 
development of GC.
Our experimental results confirmed that CRKL was a 
target of miR-335 in GC cells. Overexpression of miR-335 
significantly reduced the activity of a luciferase reporter 
containing the 3′UTR sequence of CRKL, while muta-
tion of the seed region sites in the 3′UTR abolished the 
regulatory effect of miR-335. Furthermore, restoration 
of miR-335 down-regulated CRKL protein expression 
post-transcriptionally. These study thus clearly suggest 
that miR-335 may directly regulate CRKL expression by 
inducing mRNA degradation and translational suppres-
sion. Collectively, down-regulation of miR-335 may thus 
contribute to gastric carcinogenesis, at least partly via 
up-regulation of CRKL.
Conclusion
This study demonstrated for the first time that miR-335 
was dramatically down-regulated in GC, and revealed 
that low expression of miR-335 was associated with 
tumor size, venous invasion, peritoneal dissemination, 
lymph node metastasis, poor pT stage, poor pN stage, 
poor TNM stage, invasion into lymphatic vessels, and 
shorter DFS. Moreover, restoration of miR-335 sup-
pressed GC cell proliferation, migration, and invasion, 
arrested the cell cycle, and increased GC cell apoptosis. 
MiR-335 thus functions as a tumor suppressor in GC. To 
the best of our knowledge, this study also provides the 
first evidence for associations between hypermethylation 
of the miR-335 promoter region and its expression, and 
between hypermethylation status and shorter DFS, inva-
sion into lymphatic vessels, and large tumor size, which 
could be predictive factors for tumor prognosis and 
Fig. 7 Impact of miR‑335 on GC cell migration, invasion, and proliferation. a, b Wound‑healing assay in SGC‑7901 cells. Quantitative values indicate 
the mean distance ± SD between the migration fronts measured at different time‑points per three wells, and are representative of three experi‑
ments. Cells treated with 5‑aza closed the wound significantly slower than untreated cells. *P < 0.05 between groups. c Cell proliferation of 5‑aza‑
treated SGC‑7901 and MKN‑45 cells was assessed by MTT assay. Values are expressed as the mean ± SD of three experiments. Cell proliferation was 
significantly lower in SGC‑7901 and MKN‑45 cells treated with 5‑aza compared with untreated and parental cells. *P < 0.05
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biological behavior in GC tissues. The effects of miR-
335 on GC cell migration, invasion, and proliferation 
observed in this study may be partly due to its regula-
tion of CRKL. These data warrant further investigations 
of the miR-335/CRKL axis as a prospective therapeutic 
target in the treatment of GC. Further large-scale and 
long-term follow-up studies focusing on the methyla-
tion status of miR-335 in GC should be undertaken in 
the future.
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